Immuneering Corp (IMRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.82-4.37%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IMRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
IMRX — earnings miss
Dated 2026-08-05
of this Current Report, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Why it matters: If health care revenue growth picks up, it may help Immuneering's outlook. A strong sector can lift all companies.
Supportive ifHealth care revenue growth shows a return to near 10% or higher.
Worry ifHealth care revenue growth keeps slowing down below current levels.
Why it matters: Litigation may affect the trial and the company's image. This impacts investor trust.
Worry ifRecent updates say the lawsuit ended well for the company.
Less concerning ifThere are reports of bad news about the lawsuit.
Why it matters: Extending cash runway is crucial for funding operations until 2029. This affects survival and growth.
Supportive ifAn announcement of new funding or partnerships that extend the cash runway is made.
Worry ifNo new funding sources are found. This may lead to cuts.
Why it matters: Updates on patient dosing will show progress in the trial for atebimetinib. This trial is for pancreatic cancer.
Supportive ifAnnouncement of the first patient dosed in the MAPKeeper 301 trial.
Worry ifNo updates on patient dosing or delays in trial recruitment.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$239 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $768 loss on $10,000 · 7.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,767 loss on $10,000 · 57.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on the trial will show if the drug is effective. This affects the company's future.
Supportive ifPositive results from the Phase 2a trial are announced.
Worry ifNegative results or delays in the trial are reported.
Why it matters: New survival data could show how well atebimetinib works for first-line pancreatic cancer. This may bring more interest in the drug.
Supportive ifThe presentation shows that patients with first-line pancreatic cancer live more than 17.3 months.
Worry ifThe presentation shows that patients live less than 17.3 months or see no big change.
Why it matters: The lawsuit could affect the company's reputation and future work.
Worry ifThe company states that the lawsuit is resolved in a positive way.
Less concerning ifNew developments in the lawsuit could show possible problems or bad results.
Why it matters: Starting this trial shows progress in using atebimetinib for more than pancreatic cancer. It may create new market chances.
Supportive ifFirst patient is dosed in the Phase 2 trial of atebimetinib plus anti-PD-1 in non-small cell lung cancer.
Worry ifDelay in dosing the first patient in the Phase 2 trial beyond 2H 2026.
Why it matters: This data will show how well atebimetinib works in first-line pancreatic cancer. Positive results could boost confidence in the drug's potential.
Supportive ifThe MAPKeeper 301 trial shows that median overall survival is more than 17.3 months.
Worry ifTopline data shows median overall survival less than 17.3 months.
Why it matters: Updates on cash runway will indicate financial health. A longer runway supports ongoing trials and operations.
Watch forCash runway is confirmed to extend into 2029.
Also watch forThe cash runway now shows funding problems may happen before 2029.